MESA LABORATORIES INC (MLAB) Fundamental Analysis & Valuation

NASDAQ:MLAB • US59064R1095

Current stock price

77.96 USD
+0.15 (+0.19%)
At close:
77.96 USD
0 (0%)
After Hours:

This MLAB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. MLAB Profitability Analysis

1.1 Basic Checks

  • In the past year MLAB was profitable.
  • MLAB had a positive operating cash flow in the past year.
  • In multiple years MLAB reported negative net income over the last 5 years.
  • In the past 5 years MLAB always reported a positive cash flow from operatings.
MLAB Yearly Net Income VS EBIT VS OCF VS FCFMLAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M

1.2 Ratios

  • The Return On Assets of MLAB (0.86%) is better than 64.91% of its industry peers.
  • With a decent Return On Equity value of 2.00%, MLAB is doing good in the industry, outperforming 66.67% of the companies in the same industry.
  • MLAB has a better Return On Invested Capital (3.58%) than 64.91% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for MLAB is significantly below the industry average of 11.85%.
  • The last Return On Invested Capital (3.58%) for MLAB is above the 3 year average (2.10%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 0.86%
ROE 2%
ROIC 3.58%
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)2.1%
ROIC(5y)1.72%
MLAB Yearly ROA, ROE, ROICMLAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150

1.3 Margins

  • MLAB's Profit Margin of 1.51% is fine compared to the rest of the industry. MLAB outperforms 64.91% of its industry peers.
  • MLAB's Operating Margin of 6.96% is fine compared to the rest of the industry. MLAB outperforms 64.91% of its industry peers.
  • In the last couple of years the Operating Margin of MLAB has grown nicely.
  • Looking at the Gross Margin, with a value of 62.40%, MLAB belongs to the top of the industry, outperforming 80.70% of the companies in the same industry.
  • In the last couple of years the Gross Margin of MLAB has grown nicely.
Industry RankSector Rank
OM 6.96%
PM (TTM) 1.51%
GM 62.4%
OM growth 3Y41.92%
OM growth 5Y1.93%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.16%
GM growth 5Y2.74%
MLAB Yearly Profit, Operating, Gross MarginsMLAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. MLAB Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), MLAB is destroying value.
  • Compared to 1 year ago, MLAB has more shares outstanding
  • MLAB has more shares outstanding than it did 5 years ago.
  • MLAB has a better debt/assets ratio than last year.
MLAB Yearly Shares OutstandingMLAB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M 5M
MLAB Yearly Total Debt VS Total AssetsMLAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of 1.30, we must say that MLAB is in the distress zone and has some risk of bankruptcy.
  • MLAB's Altman-Z score of 1.30 is in line compared to the rest of the industry. MLAB outperforms 47.37% of its industry peers.
  • MLAB has a debt to FCF ratio of 4.41. This is a neutral value as MLAB would need 4.41 years to pay back of all of its debts.
  • MLAB has a better Debt to FCF ratio (4.41) than 71.93% of its industry peers.
  • A Debt/Equity ratio of 0.86 indicates that MLAB is somewhat dependend on debt financing.
  • MLAB has a worse Debt to Equity ratio (0.86) than 78.95% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF 4.41
Altman-Z 1.3
ROIC/WACC0.34
WACC10.59%
MLAB Yearly LT Debt VS Equity VS FCFMLAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.3 Liquidity

  • MLAB has a Current Ratio of 1.94. This is a normal value and indicates that MLAB is financially healthy and should not expect problems in meeting its short term obligations.
  • MLAB has a Current ratio of 1.94. This is in the lower half of the industry: MLAB underperforms 63.16% of its industry peers.
  • MLAB has a Quick Ratio of 1.45. This is a normal value and indicates that MLAB is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.45, MLAB is not doing good in the industry: 68.42% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.94
Quick Ratio 1.45
MLAB Yearly Current Assets VS Current LiabilitesMLAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. MLAB Growth Analysis

3.1 Past

  • MLAB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -87.40%.
  • Measured over the past years, MLAB shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -39.16% on average per year.
  • The Revenue has been growing slightly by 4.12% in the past year.
  • Measured over the past years, MLAB shows a quite strong growth in Revenue. The Revenue has been growing by 15.41% on average per year.
EPS 1Y (TTM)-87.4%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%351.94%
Revenue 1Y (TTM)4.12%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%3.64%

3.2 Future

  • MLAB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 247.51% yearly.
  • Based on estimates for the next years, MLAB will show a small growth in Revenue. The Revenue will grow by 4.11% on average per year.
EPS Next Y3244.14%
EPS Next 2Y354.08%
EPS Next 3Y247.51%
EPS Next 5YN/A
Revenue Next Year4.19%
Revenue Next 2Y4.8%
Revenue Next 3Y4.11%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
MLAB Yearly Revenue VS EstimatesMLAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M 250M
MLAB Yearly EPS VS EstimatesMLAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

5

4. MLAB Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 121.81, the valuation of MLAB can be described as expensive.
  • The rest of the industry has a similar Price/Earnings ratio as MLAB.
  • The average S&P500 Price/Earnings ratio is at 25.70. MLAB is valued rather expensively when compared to this.
  • A Price/Forward Earnings ratio of 54.02 indicates a quite expensive valuation of MLAB.
  • MLAB's Price/Forward Earnings ratio is in line with the industry average.
  • When comparing the Price/Forward Earnings ratio of MLAB to the average of the S&P500 Index (23.84), we can say MLAB is valued expensively.
Industry RankSector Rank
PE 121.81
Fwd PE 54.02
MLAB Price Earnings VS Forward Price EarningsMLAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • MLAB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MLAB is cheaper than 84.21% of the companies in the same industry.
  • 92.98% of the companies in the same industry are more expensive than MLAB, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 11.42
EV/EBITDA 13.41
MLAB Per share dataMLAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of MLAB may justify a higher PE ratio.
  • MLAB's earnings are expected to grow with 247.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y354.08%
EPS Next 3Y247.51%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. MLAB Dividend Analysis

5.1 Amount

  • With a yearly dividend of 0.73%, MLAB is not a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 0.10, MLAB pays a better dividend. On top of this MLAB pays more dividend than 96.49% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, MLAB's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.73%

5.2 History

  • The dividend of MLAB decreases each year by -0.50%.
  • MLAB has paid a dividend for at least 10 years, which is a reliable track record.
  • MLAB has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)-0.5%
Div Incr Years0
Div Non Decr Years21
MLAB Yearly Dividends per shareMLAB Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6

5.3 Sustainability

  • MLAB pays out 93.97% of its income as dividend. This is not a sustainable payout ratio.
DP93.97%
EPS Next 2Y354.08%
EPS Next 3Y247.51%
MLAB Yearly Income VS Free CF VS DividendMLAB Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M -200M -250M
MLAB Dividend Payout.MLAB Dividend Payout, showing the Payout Ratio.MLAB Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

MLAB Fundamentals: All Metrics, Ratios and Statistics

MESA LABORATORIES INC

NASDAQ:MLAB (3/13/2026, 8:00:00 PM)

After market: 77.96 0 (0%)

77.96

+0.15 (+0.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-03
Earnings (Next)05-26
Inst Owners92.09%
Inst Owner Change-4%
Ins Owners5.44%
Ins Owner Change3.15%
Market Cap430.34M
Revenue(TTM)247.54M
Net Income(TTM)3.73M
Analysts80
Price Target106.59 (36.72%)
Short Float %4.06%
Short Ratio2.26
Dividend
Industry RankSector Rank
Dividend Yield 0.73%
Yearly Dividend0.64
Dividend Growth(5Y)-0.5%
DP93.97%
Div Incr Years0
Div Non Decr Years21
Ex-Date02-27
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)153.03%
Min EPS beat(2)130.33%
Max EPS beat(2)175.74%
EPS beat(4)3
Avg EPS beat(4)44.77%
Min EPS beat(4)-217.83%
Max EPS beat(4)175.74%
EPS beat(8)5
Avg EPS beat(8)420.17%
EPS beat(12)6
Avg EPS beat(12)229.7%
EPS beat(16)8
Avg EPS beat(16)172.52%
Revenue beat(2)1
Avg Revenue beat(2)-0.59%
Min Revenue beat(2)-1.95%
Max Revenue beat(2)0.77%
Revenue beat(4)1
Avg Revenue beat(4)-1.45%
Min Revenue beat(4)-3.63%
Max Revenue beat(4)0.77%
Revenue beat(8)4
Avg Revenue beat(8)0.47%
Revenue beat(12)4
Avg Revenue beat(12)-1.22%
Revenue beat(16)6
Avg Revenue beat(16)-1.01%
PT rev (1m)5.56%
PT rev (3m)10%
EPS NQ rev (1m)-3.77%
EPS NQ rev (3m)-3.77%
EPS NY rev (1m)19.12%
EPS NY rev (3m)19.12%
Revenue NQ rev (1m)1.07%
Revenue NQ rev (3m)1.07%
Revenue NY rev (1m)1.06%
Revenue NY rev (3m)1.06%
Valuation
Industry RankSector Rank
PE 121.81
Fwd PE 54.02
P/S 1.74
P/FCF 11.42
P/OCF 10.36
P/B 2.31
P/tB N/A
EV/EBITDA 13.41
EPS(TTM)0.64
EY0.82%
EPS(NY)1.44
Fwd EY1.85%
FCF(TTM)6.83
FCFY8.76%
OCF(TTM)7.52
OCFY9.65%
SpS44.84
BVpS33.82
TBVpS-16.71
PEG (NY)0.04
PEG (5Y)N/A
Graham Number22.07
Profitability
Industry RankSector Rank
ROA 0.86%
ROE 2%
ROCE 4.53%
ROIC 3.58%
ROICexc 3.87%
ROICexgc 18.77%
OM 6.96%
PM (TTM) 1.51%
GM 62.4%
FCFM 15.23%
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)2.1%
ROIC(5y)1.72%
ROICexc(3y)2.32%
ROICexc(5y)2.16%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)2.66%
ROCE(5y)2.18%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y111.19%
ROICexc growth 5Y22.93%
OM growth 3Y41.92%
OM growth 5Y1.93%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.16%
GM growth 5Y2.74%
F-Score6
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF 4.41
Debt/EBITDA 3.81
Cap/Depr 15.35%
Cap/Sales 1.55%
Interest Coverage 250
Cash Conversion 98.31%
Profit Quality 1009.48%
Current Ratio 1.94
Quick Ratio 1.45
Altman-Z 1.3
F-Score6
WACC10.59%
ROIC/WACC0.34
Cap/Depr(3y)13.3%
Cap/Depr(5y)13.77%
Cap/Sales(3y)1.71%
Cap/Sales(5y)1.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-87.4%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%351.94%
EPS Next Y3244.14%
EPS Next 2Y354.08%
EPS Next 3Y247.51%
EPS Next 5YN/A
Revenue 1Y (TTM)4.12%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%3.64%
Revenue Next Year4.19%
Revenue Next 2Y4.8%
Revenue Next 3Y4.11%
Revenue Next 5YN/A
EBIT growth 1Y-4.88%
EBIT growth 3Y55.19%
EBIT growth 5Y17.63%
EBIT Next Year193.28%
EBIT Next 3Y47.61%
EBIT Next 5YN/A
FCF growth 1Y-7.43%
FCF growth 3Y6.74%
FCF growth 5Y10.67%
OCF growth 1Y-5.11%
OCF growth 3Y6.07%
OCF growth 5Y11.64%

MESA LABORATORIES INC / MLAB Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for MESA LABORATORIES INC?

ChartMill assigns a fundamental rating of 5 / 10 to MLAB.


What is the valuation status of MESA LABORATORIES INC (MLAB) stock?

ChartMill assigns a valuation rating of 5 / 10 to MESA LABORATORIES INC (MLAB). This can be considered as Fairly Valued.


How profitable is MESA LABORATORIES INC (MLAB) stock?

MESA LABORATORIES INC (MLAB) has a profitability rating of 7 / 10.


What is the financial health of MESA LABORATORIES INC (MLAB) stock?

The financial health rating of MESA LABORATORIES INC (MLAB) is 3 / 10.


Can you provide the expected EPS growth for MLAB stock?

The Earnings per Share (EPS) of MESA LABORATORIES INC (MLAB) is expected to grow by 3244.14% in the next year.